Similar Articles
New molecule in Parkinson’s disease treatment: Safinamide (monoamine oxidase-B plus inhibitor)
Murat Gültekin, Beyzanur Altıkulaç Ilikhan
DOI: 10.5606/phhb.dergisi.2025.49
Issue: 2025, Volume 28 - Issue 2-3
2495
1277
A case of Parkinson’s disease with clinical deterioration specific to constipation periods
Funda Kaplan, Zehra Yavuz, Özlem Munis Bizpınar, Selim Selçuk Çomoğlu
DOI: 10.5606/phhb.dergisi.2025.33
Issue: 2025, Volume 28 - Issue 2-3
707
763
Beta-ureidopropionase deficiency as a rare cause of dystonia
Dilek İşcan, Zehra Yavuz, Selim Selçuk Çomoğlu
DOI: 10.5606/phhb.dergisi.2025.36
Issue: 2025, Volume 28 - Issue 2-3
489
707
REM sleep behavior disorder in benign and malignant Parkinson’s disease: A comparative analysis of clinical and questionnaire-based findings
Nilay Padir Sensoz, Asya Kosereisoglu, Tülin Akturk, Banu Ozen Barut
DOI: 10.5606/phhb.dergisi.2026.73
Issue: 2026, Volume 29 - Issue 1
325
499
Candidate profile and clinical characteristics of patients undergoing STN-DBS surgery for advanced Parkinson's disease: A single-center experience
Gülce Coşku Yılmaz Çakan, Gökhan Gürkan, Ali Akay, Özge Yılmaz Küsbeci
DOI: 10.5606/phhb.dergisi.2026.71
Issue: 2026, Volume 29 - Issue 2
93
81